Parkinson’s disease can lead to early retinal changes — alterations in the thin layer at the back of the eye, known as the retina, that’s responsible for detecting light and sending visual signals to the brain — that can be revealed with the use of a simple eye test,…
Researchers for the first time visualized how PINK1, a protein linked to early-onset Parkinson’s disease, binds to mitochondria and how it’s switched on to protect these energy-producing structures when they’re damaged. Using a high-resolution microscope to map the structure of the human version of PINK1 bound to damaged mitochondria,…
Neurons, or nerve cells, that release a signaling molecule called glutamate within the enteric nervous system — a network of nerve cells embedded in the gut wall — play a crucial role in regulating bowel movements, according to a Stanford University study that ultimately could lead to new ways to…
The first patient has been dosed in Gain Therapeutics‘ clinical trial of GT-02287, an investigational, oral small molecule being developed for treating Parkinson’s disease. With several locations open in Australia, the Phase 1b clinical trial (NCT06732180) is still recruiting up to 20 adults, ages 30-85, who’ve been…
A rare nerve disorder may offer clues to potential Parkinson’s disease treatment targets, a mouse study showed. In giant axonal neuropathy (GAN), buildup of neurofilament proteins trap several cellular organelles and proteins, preventing nerve cells from clearing and recycling waste, the study found. Because neurofilament proteins have also been…
Right Brain Bio is repurposing the approved therapy RB-190 as a treatment for Parkinson’s disease — and is now preparing to seek U.S. Food and Drug Administration (FDA) clearance to test the anticancer medication for this indication in a Phase 2 clinical trial. The company intends to file…
Note: This story was updated March 17, 2025, to correct the attribution of quotes to Sonya Dumanis, PhD, deputy director of Aligning Science Across Parkinson’s. The Aligning Science Across Parkinson’s (ASAP) initiative is investing $6 million in research grants to support the development of new tools — including cell…
A small Phase 1 clinical trial testing a treatment approach that uses stem cells derived from a patient’s blood cells to replace the dopamine-producing neurons progressively lost in Parkinson’s disease is looking for three more patients. The first-of-its-kind Phase 1 study (NCT06422208), being conducted at Harvard Medical School’s…
The number of people with Parkinson’s disease is likely to more than double in the next years, topping 25 million worldwide by 2050, mainly because the world’s population is living longer, a study found. The largest increases are projected to be in East Asia, where nearly 11 million people…
A daily dose of CPL’36, an oral small molecule in the pipeline of Celon Pharma, may ease symptoms for patients who experience levodopa-induced dyskinesia, or uncontrolled movements as a side effect of the mainstay Parkinson’s disease treatment, within one week. That’s according to data from a Phase 2 clinical…
Get regular updates to your inbox.
